Europe Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type (Cell Therapy {Allogeneic, Autologous, and Viral Vectors}, and Gene Therapy {Non-viral Vectors, and Viral Vectors}), Services (Process Development, cGMP Manufacturing, Regu

The Europe cell and gene therapy market was valued at US$ 1,105.10 million in 2023 and is projected to reach US$ 5,334.44 million by 2031; it is estimated to record a CAGR of 21.7% from 2023 to 2031.

Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing Drives Europe Cell and Gene Therapy Market

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and monitoring of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual and open manufacturing method, as well as building a more commercially suitable process, can be challenging. Therefore, these manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs support product development, manufacturing, clinical trials, and commercialization services to cell and gene therapy companies on a contract basis. Under the partnership with a CDMO, cell and gene therapy manufacturers support scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. Outsourcing cell and gene therapy manufacturing to CDMOs proves to be cost-effective for manufacturers. They gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the Europe cell and gene therapy market growth.

Europe Cell and Gene Therapy Market Overview

The cell and gene therapy market in Germany is expected to witness significant growth during the forecast period due to factors such as investment in the setup of production capacity, high government support, and involvement in the region. Also, the presence of top competitive players will enhance the regional market growth during the forecast period. Germany has a strong pharmaceutical industry with a notable focus on R&D. The country has 660 biotechnology companies that employ 50,000 employees. Among these, 660 companies are focused on cell and gene therapies (CGTs). As per the NecstGen report, more than 29 active clinical trials evaluating CAR-modified immune cells were ongoing in 2023, and most of the production involved CAR-T cells. Also, over 50 clinical studies have been conducted in gene therapy in Germany so far. The innovation efforts of German CGT companies are majorly focused on the local or country level, as they lack international presence.

Europe Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Europe Cell and Gene Therapy Market Segmentation

The Europe cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Europe cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Europe cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Europe cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Europe cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Europe cell and gene therapy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe cell and gene therapy market share in 2023.

Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Europe cell and gene therapy market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cell and gene therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe cell and gene therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe cell and gene therapy market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.